about
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancerTyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinasesAndrogen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy.Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation.Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation.ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancerProtein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation.Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axisAndrogen receptor epigenetics.A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancerSOX9 drives WNT pathway activation in prostate cancer.Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity.Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancerAndrogen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2.Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion.SUMO-3 enhances androgen receptor transcriptional activity through a sumoylation-independent mechanism in prostate cancer cells.ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.Positive feedback loop mediated by protein phosphatase 1α mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer.Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein.Discovery of a selective irreversible BMX inhibitor for prostate cancer.LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression.Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155.Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.Makorin RING finger protein 1 (MKRN1) has negative and positive effects on RNA polymerase II-dependent transcription.Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells.c-Jun has multiple enhancing activities in the novel cross talk between the androgen receptor and Ets variant gene 1 in prostate cancerBMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate CancerTMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cellsForkhead domain mutations in FOXA1 drive prostate cancer progression
P50
Q30538848-9C19AFBE-57B0-4B49-90C3-8EA439D49BC1Q34424735-3B9CB7E9-81E7-4EA4-8431-83209553059AQ34743655-565E6572-7FB9-4847-81B9-2342BBBB9CFFQ35575633-1201ABF6-6FF2-4855-BF4C-F67CD93AF650Q35612095-639CB5E8-D3ED-456F-8530-593DC42002E2Q35694048-D359A161-5062-4015-89A6-7DD289461C51Q35868187-E286C563-1E29-491E-AA7C-AEB573A01D52Q36638207-7B56D79D-B7BF-4E91-9913-F9A4332425EFQ36738961-9EF31EEA-F90D-46F6-8CB7-97D1A631E325Q36961208-77F6932C-197D-49C7-9F9E-45F3AB6A12B8Q38314940-1B9754D9-76D3-4E57-8503-74B59080403EQ38723579-B447DFE6-1725-493B-B576-D7367161A8E6Q38780862-479AFDC7-0C0A-4869-932C-6EA6FD555FCAQ38931537-888B7572-897A-4CAE-96A3-7AE685901F2AQ39647282-CD1F67B4-2BA6-47C3-AEEA-7C59A8D437A9Q39827834-0D8D0B08-0235-4C07-89E4-1FC6ABA3F7AEQ39843676-49862629-34D1-4C18-9FCD-D64BB53FE455Q39983820-00393083-77F6-4D21-8867-C400E649A3ABQ40132532-76823EBC-F794-48D6-9A81-A2CB2D87B340Q40339120-C30305B3-C266-4AE2-8863-F2FF6B722300Q41768007-08F3FDF7-0092-4030-B223-5D022082DDA9Q41812923-45B9E9B8-8DE0-4A2C-977D-34F8D07DC284Q42006129-CAC15ED6-1272-407B-8EBA-2187BBD94E76Q42363301-AE419034-5E4E-4655-891E-C7E57F76F3C6Q42711869-8DE23171-9641-4187-BFDD-AD35D74F06BBQ44020966-DCA62FB3-5FE7-4AED-8D06-26468059EB86Q45058251-4A63D496-D0BC-4480-A14D-7A92575B00FCQ50068799-9C580849-D563-447B-8206-4DE8B7C29587Q52571560-D3499B12-E846-4F2D-98B7-5DD94970146BQ52573861-2536E5D0-1476-4461-A590-916D2A6BA669Q80624465-333E206D-BD23-4EF0-B1F4-6C841858E795Q90253010-8F90D0E8-9CE5-444E-B277-729E9C412055Q91341634-E17DF55C-3F04-4923-AB1C-5DBEF12C9BACQ92035659-96486E15-1B37-4A76-A7A1-630FBDF1CBF2
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Changmeng Cai
@ast
Changmeng Cai
@en
Changmeng Cai
@es
Changmeng Cai
@nl
Changmeng Cai
@sl
type
label
Changmeng Cai
@ast
Changmeng Cai
@en
Changmeng Cai
@es
Changmeng Cai
@nl
Changmeng Cai
@sl
prefLabel
Changmeng Cai
@ast
Changmeng Cai
@en
Changmeng Cai
@es
Changmeng Cai
@nl
Changmeng Cai
@sl
P106
P1153
12793309300
P31
P496
0000-0002-8701-2586